Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Transthyretin Amyloidosis Treatment Market to hit $35.1B by 2035, growing at 14.64% CAGR driven by new RNAi therapies and diagnostics.

Market News
07 Jul 2026
Sns Insider
View Source
Bullish
pluang ai news

The global Transthyretin Amyloidosis Treatment Market, valued at $8.95 billion in 2025, is projected to reach $35.10 billion by 2035 with a CAGR of 14.64%. Growth is fueled by advances in gene-silencing RNAi therapies like patisiran and vutrisiran, improved diagnostic imaging, and increased diagnosis rates of ATTR cardiomyopathy. North America leads with 46% market share, supported by strong healthcare infrastructure and regulatory approvals, while Asia Pacific is the fastest-growing region due to rising awareness and healthcare improvements. Pipeline drugs such as acoramidis and eplontersen promise further market expansion through enhanced efficacy and safety profiles.

More News (ALNY)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App